Cerity Partners’s Cartesian Therapeutics RNAC Stock Holding History

Cerity Partners’s Portfolio RNAC Stock Details RNAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-667	Closed	-$57K	–	524
2020 Q2	$57K	Buy	+667	New	+$60.5K	﹤0.01%	447

Other funds holding RNAC

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

MWNA

Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

PVMCV

Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

Cerity Partners's RNAC Position: Q3 2020 in Review

Cerity Partners sold out of Cartesian Therapeutics (RNAC) in Q3 2020, closing a stake of 667 shares — an estimated $57K sold.

Cerity Partners first reported a position in RNAC in Q2 2020 and held it in 1 quarter. The position peaked at $57K in Q2 2020. 79 funds tracked by Wall St. Rank hold RNAC as of Q3 2020.

Cerity Partners reported no remaining Cartesian Therapeutics position as of Q3 2020 after selling out during the quarter.
Cerity Partners sold 667 Cartesian Therapeutics shares in Q3 2020, an estimated $57K.
Cerity Partners first reported a position in Cartesian Therapeutics in Q2 2020 and held it in 1 quarter.
Cerity Partners's Cartesian Therapeutics position peaked at $57K in Q2 2020.
79 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q3 2020.

Based on Cerity Partners's 13F filing for Q3 2020, filed 12 Nov 2020.